Adaptive Biotechnologies Corp (ADPT) CSO exercises options and sells 492,400 shares

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp chief scientific officer Harlan S. Robins exercised a fully vested stock option for 284,800 shares of common stock at $6.55 per share and sold 492,400 shares in two transactions at weighted-average prices of $21.72 and $22.12 on July 21, 2026.

All reported trades were effected under a Rule 10b5-1 trading plan adopted on March 13, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider ROBINS HARLAN S

Role Chief Scientific Officer

Sold 492,400 shs ($10.78M)

Approx. gross sale proceeds $10.78M

Approx. exercise cost $1.87M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F4	284,800	$0.00	$0.00
Exercise	Common Stock F1	284,800	$6.55	$1.87M
Sale	Common Stock F1, F2	278,698	$21.72	$6.05M
Sale	Common Stock F1, F3	213,702	$22.12	$4.73M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 812,058 shares (Direct)

Footnotes (4)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
2. F2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
3. F3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
4. F4. The option was fully vested and exercisable.

Key Figures

Options Exercised: 284,800 shares Exercise Price: $6.55 per share Shares Sold: 492,400 shares +3 more

6 metrics

Options Exercised 284,800 shares Stock option (right to buy) exercised on July 21, 2026

Exercise Price $6.55 per share Exercise or conversion price of the stock option

Shares Sold 492,400 shares Total ADPT common shares sold across two transactions

Weighted-Average Sale Price 1 $21.72 per share First sale, trades ranged from $20.90 to $21.89

Weighted-Average Sale Price 2 $22.12 per share Second sale, trades ranged from $21.90 to $22.47

Option Expiration February 7, 2028 Expiration date of the exercised stock option grant

Key Terms

Rule 10b5-1 trading plan, weighted-average price, Stock Option (right to buy), fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported for this transaction is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

fully vested and exercisable financial

"The option was fully vested and exercisable."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/23/2026 - 07:35 PM Accepted by SEC EDGAR 07/23/2026 - 07:34 PM Learn about SEC filing dates

FAQ

What did ADPT insider Harlan S. Robins report in this Form 4?

Harlan S. Robins, chief scientific officer of Adaptive Biotechnologies (ADPT), reported exercising a stock option for 284,800 shares at $6.55 per share and selling 492,400 common shares in two transactions on July 21, 2026.

How many Adaptive Biotechnologies (ADPT) shares were sold and at what prices?

The filing shows sales of 492,400 shares of ADPT common stock. The shares were sold in two weighted-average price transactions at $21.72 and $22.12 per share, each executed across multiple trades within stated price ranges.

What stock option exercise did the ADPT chief scientific officer report?

The chief scientific officer exercised a fully vested stock option covering 284,800 shares of Adaptive Biotechnologies common stock at an exercise price of $6.55 per share. Following this exercise, the specific option grant reported showed 0 derivative shares remaining.

Were the reported ADPT trades made under a Rule 10b5-1 plan?

Yes. All transactions in the filing were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026, indicating the trades followed a pre-arranged schedule rather than discretionary timing.

What price ranges applied to the ADPT share sales in this Form 4?

The first sale, with a weighted-average price of $21.72, occurred in trades ranging from $20.90 to $21.89 per share. The second, averaging $22.12, involved trades between $21.90 and $22.47 per share, according to the footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS HARLAN S

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/21/2026		M(1)		284,800	A	$6.55	1,304,458	D
Common Stock	07/21/2026		S(1)		278,698	D	$21.72(2)	1,025,760	D
Common Stock	07/21/2026		S(1)		213,702	D	$22.12(3)	812,058	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.55	07/21/2026		M(1)			284,800	(4)	02/07/2028	Common Stock	284,800	$0	0	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The option was fully vested and exercisable.

	/s/ Harlan S Robins by Kyle Piskel, Attorney-in-Fact	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)